Drug Development

#ESMO18: Cardio dreams blighted, Novartis showcases its “blockbuster” ambitions for radiopharmaceuticals

Venture Capital

TP Therapeutics grabs $80M mezzanine round to fund a pivotal trial for ROS-1/NTRK-positive cancers

Immuno-oncology, Results

Merck previews an early hit with Keytruda combo for kidney cancer, putting more pressure on rival Bristol-Myers
More news caret

calendar Protocols

Quick hits from around the biopharma web

Oct 18

Takeda gets Japanese antitrust regulators' blessing for Shire deal; France's Acticor Biotech raises €15.3M for stroke drug

Oct 17

Novotech beefs up Asia-Pacific CRO offering with new buyout as region’s biopharma business booms

Oct 16

Genentech builds new office in Oregon after trimming HQ staff; Researchers laud ketamine as a replacement for opioids

Oct 15

Alnylam shares dip on a decision to scrap accelerated pitch on givosiran; Loxo gets a 'breakthrough' at the FDA

More Protocols caret

person Peer Review

Weekly biopharma careers news report

Oct 19

Medivir taps ex-Acadia chief Uli Hacksell as interim CEO; Merck onboards chief digital officer

Oct 12

Perrigo taps ex-tobacco exec as new CEO; Dana Farber T cell investigator Nick Haining joins Merck

Oct 5

Belgian upstart Rewind taps Ian Reynolds as CEO; Robert Foster takes the reins at ContraVir

Oct 1

Ian Read taps his carefully groomed successor Albert Bourla as the next Pfizer CEO. What's his future look like?

More peer review caret

Dollar Premium

Exclusive: At Hal Barron’s R&D group at GSK, consensus is out, leaders are in and watch out for an ‘intense drive’ to spur the late-stage pipeline

With its rep on the line, Celgene's newly-filed safety study spurs fresh worries over fate of ozanimod

A go-go FDA is poised to break the all-time record on new drug approvals. Is this the new standard for biopharma success?

Global reach: The top 25 biopharma companies in the world

Genentech team does some cutting-edge work on a new class of antibiotics — here's why that's important

The high-roller club in biopharma: Who’s paying top-dollar for upfronts? And who are the busiest players at the deal table?

bullhorn Bioregnum

The view from John Carroll

Oct 3

Sarepta shares yo-yo in the red on another glimpse of stellar results for Duchenne MD gene therapy — what gives?

Sep 13

Genentech team does some cutting-edge work on a new class of antibiotics — here's why that's important

Sep 6

Juno will pay $24M to settle the JCAR015 scandal — but don’t expect that to change industry attitudes on reporting snafus

Aug 13

Vertex’s fight club rule: Block new treatments to cystic fibrosis patients until Orkambi is reimbursed properly

More opinion caret

twitter Marco

Hot BioTwitter bot - last updated ago

arrow-thick Most Viral

Immunotherapy as Second-line in Patient With Small Cell Lung Cancer - Full Text View - ClinicalTrials.gov

ClinicalTrials a day

Head of IBM Watson Health leaving post after company stumbles, growing criticism

STAT a day

Clovis, with new study data, hopes to be first to develop a PARP for prostate cancer

STAT a day

Idera Pharmaceuticals Presents Data from the ILLUMINATE-204 Trial of the Combination of Tilsotolimod and Ipilimumab for Unresectable or Metastatic Melanoma Following Failure of PD-1 Inhibitor Treatment at the 2018 European Society for Medical Oncology (ESMO) Congress

GlobeNewswire News Room Idera Pharmaceuticals, Inc. a day

The 14 Social Media Etiquette Rules: Biotech Investor Edition

Forbes a day

WSJ Health Weekly - Food labels, biosimilars and more...

Createsend a day

Orphan Drugs in the United States

Iqvia a day

Scientists argue heart stem cell trial should be paused

Washington Post a day

A tailormade drug developed in record time may save girl from fatal brain disease

Science | AAAS a day

Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 15-18 October 2018

Europa a day

timer Latest

Science | AAAS

A tailormade drug developed in record time may save girl from fatal brain disease

New York Times

Opinion | Stupid Pills

Evaluate.com

Esmo 2018 - Merck & Co fails to Sting

AP News

Immunotherapy scores a first win against some breast cancers

YouTube

ESMO 2018 Congress: Highlights in metastatic triple negative breast cancer LBA1 PR

TechCrunch

China is funding the future of American biotech

GEN

Birth Method Impacts on Brain Development and Behavior | GEN

Forbes

A New Targeted Cancer Company To Watch

Scientific American

How Economic Inequality Inflicts Real Biological Harm

PR Newswire

Agenus Presents Clinical Data on Its PD-1 & CTLA-4 at ESMO 2018

fire Hot This Week

1

STAT

Harvard and the Brigham call for 31 retractions of cardiac stem cell research - STAT

2

Medicare and Medicaid Programs; Regulation to Require Drug Pricing Transparency

3

Forbes

Researchers Behind Spinraza Win Breakthrough Prize

4

STAT

Novartis buys Endocyte for $2.1 billion, and an outspoken critic admits he was wrong

5

Novartis

Novartis announces planned acquisition of Endocyte to expand expertise in radiopharmaceuticals and build on commitment to transformational therapeutic platforms

6

ClinicalTrials

Immunotherapy as Second-line in Patient With Small Cell Lung Cancer - Full Text View - ClinicalTrials.gov

7

New York Times

M.I.T. Plans College for Artificial Intelligence, Backed by $1 Billion

8

STAT

Cartoons offer a peek into cancer immunotherapy - and scientists' minds - STAT

9

Open Reading Frame

Endocyte - And now for something completely different

10

WSJ

Pharma Industry Pushes Back Against Required Listing of Drug Prices in TV Ads

Contact Endpoints News

You can also contact John Carroll, Editor at john@endpointsnews.com

← Go back
Thank you for staying with us. It's great to have you on board!
Aww, shucks. Perhaps you can tell us what we could do to make you interested in subscribing?
← Go back